ResMed Stock: Analyst Estimates & Ratings
ResMed Inc. (RMD), a global health technology company, operates across 140 countries and develops AI-powered digital health solutions, cloud-connected devices, and intelligent software to improve home healthcare. The company's shares have underperformed the broader market, decreasing 18.7% over the past 52 weeks and 3.6% year-to-date.
ResMed's market cap stands at $33.5 billion, which is below the State Street Health Care Select Sector SPDR ETF's (XLV) 28.1% increase over the same period. After reporting Q4 2026 results on Aug. 6, shares fell 5.1%, with fiscal 2027 revenue guidance between $5.75 billion and $5.85 billion falling short of analyst expectations.
The recall and suspension of the Astral ventilator, following a device correction and FDA recall linked to five serious injuries, further contributed to investor concerns over growth and supply constraints. Despite beating adjusted EPS estimates in the previous four quarters, ResMed's fiscal year 2027 adjusted EPS is expected to grow 7.7% year-over-year to $12.03.
Analysts rate the stock with a Moderate Buy consensus, based on eight Strong Buy ratings, twelve Holds, and one Strong Sell rating.
Written by urgent.news from Yahoo Finance's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
